Co-inhibition of epidermal growth factor receptor and insulin-like growth factor receptor 1 enhances radiosensitivity in human breast cancer cells

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Li, Ping ^a   Veldwijk, Marlon R ^b   Zhang, Qing ^a   Li, Zhao bin ^a   Xu, Wen cai ^a   Fu, Shen ^a  

^a SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Breast cancer; Co inhibition; Epidermal Growth Factor Receptor (EGFR); Insulin like Growth Factor Receptor 1 (IGF 1R); Radiosensitivity

Indexed keywords

3 BROMO 5 TERT BUTYL 4 HYDROXYBENZYLIDENEMALONONITRILE; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; SOMATOMEDIN C RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER PATIENT; CELL CYCLE ARREST; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; RADIOSENSITIVITY; RADIOSENSITIZATION; TREATMENT RESPONSE; TUMOR XENOGRAFT;

ANALYSIS OF VARIANCE; ANIMALS; APOPTOSIS; BREAST NEOPLASMS; DRUG SYNERGISM; ENZYME INHIBITORS; FEMALE; G1 PHASE CELL CYCLE CHECKPOINTS; HUMANS; MAP KINASE SIGNALING SYSTEM; MCF-7 CELLS; MICE; MICE, NUDE; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; QUINAZOLINES; RADIATION TOLERANCE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, IGF TYPE 1; TUMOR STEM CELL ASSAY; TYRPHOSTINS;

EID: 84879055684     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-297     Document Type: Article

References (24)

1. Voduc KD, Cheang MC, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H. Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 2010, 28:1684-1691. 10.1200/JCO.2009.24.9284, 20194857.
2. Wong FY, Chin FK, Lee KA, Soong YL, Chua ET. Hormone receptors and HER-2 status as surrogates for breast cancer molecular subtypes prognosticate for disease control in node negative Asian patients treated with breast conservation therapy. Ann Acad Med Singapore 2011, 40:90-97.
3. Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT, Perou CM. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 2006, 19:264-271. 10.1038/modpathol.3800528, 16341146.
4. Yerushalmi R, Gelmon KA, Leung S, Gao D, Cheang M, Pollak M, Turashvili G, Gilks BC, Kennecke H. Insulin-like growth factor receptor (IGF-1R) in breast cancer subtypes. Breast Cancer Res Treat 2012, 132:131-142. 10.1007/s10549-011-1529-8, 21574055.
5. Gee JM, Nicholson RI. Expanding the therapeutic repertoire of epidermal growth factor receptor blockade: radiosensitization. Breast Cancer Res 2003, 5:126-129. 10.1186/bcr584, 165000, 12793892.
6. Taunk NK, Goyal S, Moran MS, Yang Q, Parikh R, Haffty BG. Prognostic significance of IGF-1R expression in patients treated with breast-conserving surgery and radiation therapy. Radiother Oncol 2010, 96:204-208. 10.1016/j.radonc.2010.03.009, 20338651.
7. van der Veeken J, Oliveira S, Schiffelers RM. Storm G, van Bergen En Henegouwen PM, Roovers RC: Crosstalk between epidermal growth factor receptor- and insulin-like growth factor-1 receptor signaling: implications for cancer therapy. Curr Cancer Drug Targets 2009, 9:748-760. 10.2174/156800909789271495, 19754359.
8. Camirand A, Zakikhani M, Young F, Pollak M. Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells. Breast Cancer Res 2005, 7:R570-R579. 1175059, 15987464.
9. Sambade MJ, Kimple RJ, Camp JT, Peters E, Livasy CA, Sartor CI, Shields JM. Lapatinib in combination with radiation diminishes tumor regrowth in HER2+ and basal-like/EGFR + breast tumor xenografts. Int J Radiat Oncol Biol Phys 2010, 77:575-581. 10.1016/j.ijrobp.2009.12.063, 2976524, 20457354.
10. Voss MJ, Möller MF, Powe DG, Niggemann B, Zänker KS, Entschladen F. Luminal and basal-like breast cancer cells show increased migration induced by hypoxia, mediated by an autocrinemechanism. BMC Cancer 2011, 11:158. 10.1186/1471-2407-11-158, 3114792, 21535870.
11. Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, Egia A, Sasaki AT, Thomas G, Kozma SC, Papa A, Nardella C, Cantley LC, Baselga J, Pandolfi PP. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 2008, 118:3065-3074. 2518073, 18725988.
12. Shi Y, Felley-Bosco E, Marti TM, Orlowski K, Pruschy M, Stahel RA. Starvation-induced activation of ATM/Chk2/p53 signaling sensitizes cancer cells to cisplatinduced activation of ATM/Chk2/p53 signaling sensitizes cancer cells to cisplatin. BMC Cancer 2012, 12:571. 10.1186/1471-2407-12-571, 3527202, 23211021.
13. Shimizu C, Hasegawa T, Tani Y, Takahashi F, Takeuchi M, Watanabe T, Ando M, Katsumata N, Fujiwara Y. Expression of insulin-like growth factor 1 receptor in primary breast cancer: immunohistochemical analysis. Hum Pathol 2004, 35:1537-1542. 10.1016/j.humpath.2004.09.005, 15619214.
14. Jameel JK, Rao VS, Cawkwell L, Drew PJ. Radioresistance in carcinoma of the breast. Breast 2004, 13:452-460. 10.1016/j.breast.2004.08.004, 15563851.
15. Buck E, Eyzaguirre A, Rosenfeld-Franklin M, Thomson S, Mulvihill M, Barr S, Brown E, O'Connor M, Yao Y, Pachter J, Miglarese M, Epstein D, Iwata KK, Haley JD, Gibson NW, Ji QS. Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors. Cancer Res 2008, 68:8322-8332. 10.1158/0008-5472.CAN-07-6720, 18922904.
16. Luwor RB, Lu Y, Li X, Liang K, Fan Z. Constitutively active Harvey Ras confers resistance to epidermal growth factor receptor-targeted therapy with cetuximab and gefitinib. Cancer Lett 2011, 306:85-91. 10.1016/j.canlet.2011.02.035, 3102794, 21411223.
17. Wei F, Liu Y, Bellail AC, Olson JJ, Sun SY, Lu G, Ding L, Yuan C, Wang G, Hao C. K-Ras mutation-mediated IGF-1-induced feedback ERK activation contributes to the rapalog resistance. Cancer Lett 2012, 322:58-69. 10.1016/j.canlet.2012.02.005, 22342683.
18. Nicholson RI, Hutcheson IR, Knowlden JM, Jones HE, Harper ME, Jordan N, Hiscox SE, Barrow D, Gee JM. Nonendocrine pathways and endocrine resistance: observations with antiestrogens and signal transduction inhibitors in combination. Clin Cancer Res 2004, 10:346S-354S. 10.1158/1078-0432.CCR-031206, 14734490.
19. Sambade MJ, Camp JT, Kimple RJ, Sartor CI, Shields JM. Mechanism of lapatinib-mediated radiosensitization of breast cancer cells is primarily by inhibition of the Raf > MEK > ERK mitogen-activated protein kinase cascade and radiosensitization of lapatinib-resistant cells restored by direct inhibition of MEK. Radiother Oncol 2009, 93:639-644. 10.1016/j.radonc.2009.09.006, 2799330, 19853943.
20. Albert JM, Kim KW, Cao C. LuB: Targeting the Akt/mammalian target of rapamycin pathway for radiosensitization of breast cancer. Mol Cancer Ther 2006, 5:1183-1189. 10.1158/1535-7163.MCT-05-0400, 16731750.
21. Deng R, Tang J, Ma JG, Chen SP, Xia LP, Zhou WJ, Li DD, Feng GK, Zeng YX, Zhu XF. PKB/Akt promotes DSB repair in cancer cells through upregulating Mre11 expression following ionizing radiation. Oncogene 2010, 30:944-955.
22. Liang J, Slingerland JM, Slingerland JM. Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle 2003, 2:339-345.
23. Zhang Y, Wang J, Liu F, You Z, Yang R, Zhao Y. EGFR inhibitor C225 increases the radiosensitivity of human lung squamous cancer cells. Cancer Cell Int 2010, 10:39. 10.1186/1475-2867-10-39, 2972262, 20969791.
24. Dent P, Reardon DB, Park JS, Bowers G, Logsdon C, Valerie K, Schmidt-Ullrich R. Radiation-induced release of transforming growth factor alpha activates the epidermal growth factor receptor and mitogen-activated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiation-induced cell death. Mol Biol Cell 1999, 10:2493-2506. 25480, 10436007.